TY - JOUR
T1 - CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence
AU - Hirata, K.
AU - Suzuki, H.
AU - Imaeda, H.
AU - Matsuzaki, J.
AU - Tsugawa, H.
AU - Nagano, O.
AU - Asakura, K.
AU - Saya, H.
AU - Hibi, T.
PY - 2013/7/23
Y1 - 2013/7/23
N2 - Background:Multiple early gastric cancers (EGCs) may develop in 6-14% of patients even after achieving curative endoscopic submucosal dissection (ESD); however, a useful biomarker for predicting recurrence is not available. The present study investigated whether the expression of CD44 variant 9 (CD44v9), a functional cancer stem cell marker, in the primary gastric cancer tissue represents an indicator of recurrence.Methods:Eighty-eight patients who underwent ESD for EGC from 2008 to 2010 were enrolled and monitored for recurrence for 3 years. The expression levels of CD44v9 in the tissue of initial EGCs were evaluated by immunohistochemistry, and the recurrence rate was compared between CD44v9-positive and CD44v9-negative groups. The mucin phenotype and expression of microRNA-21 (miR-21) and programmed cell death protein 4 (PDCD4) were also analysed.Results:The recurrence rate of EGC was significantly higher in the CD44v9-positive group than in the CD44v9-negative group (hazard ratio (HR), 21.8; 95% confidence interval (CI), 5.71-83.1). However, mucin phenotypes and the expression of miR-21 and PDCD4 did not predict recurrence after ESD. Meanwhile, grade of gastric atrophy was also identified as a significant marker of multiple recurrence (HR, 4.95; 95% CI, 1.30-18.8).Conclusion:CD44 variant 9 expression represents a potential predictive marker for recurrence in EGC.
AB - Background:Multiple early gastric cancers (EGCs) may develop in 6-14% of patients even after achieving curative endoscopic submucosal dissection (ESD); however, a useful biomarker for predicting recurrence is not available. The present study investigated whether the expression of CD44 variant 9 (CD44v9), a functional cancer stem cell marker, in the primary gastric cancer tissue represents an indicator of recurrence.Methods:Eighty-eight patients who underwent ESD for EGC from 2008 to 2010 were enrolled and monitored for recurrence for 3 years. The expression levels of CD44v9 in the tissue of initial EGCs were evaluated by immunohistochemistry, and the recurrence rate was compared between CD44v9-positive and CD44v9-negative groups. The mucin phenotype and expression of microRNA-21 (miR-21) and programmed cell death protein 4 (PDCD4) were also analysed.Results:The recurrence rate of EGC was significantly higher in the CD44v9-positive group than in the CD44v9-negative group (hazard ratio (HR), 21.8; 95% confidence interval (CI), 5.71-83.1). However, mucin phenotypes and the expression of miR-21 and PDCD4 did not predict recurrence after ESD. Meanwhile, grade of gastric atrophy was also identified as a significant marker of multiple recurrence (HR, 4.95; 95% CI, 1.30-18.8).Conclusion:CD44 variant 9 expression represents a potential predictive marker for recurrence in EGC.
UR - http://www.scopus.com/inward/record.url?scp=84881104793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84881104793&partnerID=8YFLogxK
U2 - 10.1038/bjc.2013.314
DO - 10.1038/bjc.2013.314
M3 - Article
C2 - 23778530
AN - SCOPUS:84881104793
SN - 0007-0920
VL - 109
SP - 379
EP - 386
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 2
ER -